December 27, 2017
Rose
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health, and, more generally, innovation.
from MobiHealthNews http://ift.tt/2pKxDfq
December 27, 2017
Rose
MobiHealthNews
No comments
Related Posts:
Pear Therapeutics rakes in $50M to develop additional digital therapeutics- Canada will use AI to monitor suicidal social media posts
- MedStar Health partners with startup to pilot prenatal app
- NYT, Bloomberg say Apple is working on Watch EKG, noninvasive glucose
- Study: "Artificial pancreas" could help youth with diabetes participate in intense activities
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment